Drugs Containing Excipient (Inactive Ingredient) AMINO METHACRYLATE COPOLYMER

Last updated: August 7, 2026

Amino methacrylate copolymer is a specialty oral-solid-dose excipient used mainly for taste masking, moisture protection, and pH-dependent release control. The commercial market is concentrated around Evonik’s EUDRAGIT E family, particularly EUDRAGIT E 100 and EUDRAGIT E PO. Public data do not identify a standalone global market size or product-level revenue. Financial performance is therefore best assessed through formulation demand, regulatory adoption, pharmaceutical manufacturing trends, and Evonik’s broader Health Care business.

Amino Methacrylate Copolymer Market Dynamics and Financial Trajectory

What is amino methacrylate copolymer used for?

Amino methacrylate copolymer is a cationic methacrylate-based excipient used in oral pharmaceutical formulations. It dissolves in acidic media and becomes less soluble as pH rises, giving formulators a tool for immediate-release coating, taste masking, and protection of active pharmaceutical ingredients from moisture or processing conditions.

The principal commercial applications are:

Application	Formulation function	Commercial value
Taste masking	Coats bitter APIs and reduces release in the mouth	Supports pediatric, geriatric and chewable products
Immediate-release coating	Creates a protective film that dissolves in gastric conditions	Simplifies coating design
Moisture protection	Reduces exposure of moisture-sensitive APIs	Extends formulation stability
Subcoating	Separates incompatible API and coating layers	Supports multi-layer dosage forms
Solid dispersions and granules	Improves processability and sensory performance	Enables differentiated generics and reformulations

EUDRAGIT E 100 is supplied as a powder. EUDRAGIT E PO is a related powder grade used in pharmaceutical coating applications. The materials are manufactured by Evonik Operations GmbH and marketed through Evonik’s Health Care business.[1]

The excipient is not an active pharmaceutical ingredient, and it does not generally create product-level exclusivity. Its value comes from formulation performance, regulatory acceptability, supply reliability, and the cost of replacing validated coating systems.

Which companies supply amino methacrylate copolymer?

Evonik is the dominant publicly visible supplier of pharmaceutical amino methacrylate copolymer through the EUDRAGIT E product family. Public product documentation, regulatory references, and technical literature identify EUDRAGIT E as the principal branded platform for this chemistry.[1][2]

The competitive structure is narrower than the broader pharmaceutical excipient market because substitution requires more than matching chemical identity. A competing material must typically demonstrate:

• Comparable dissolution behavior across relevant pH ranges
• Equivalent film formation and mechanical performance
• Acceptable residual monomer and impurity profile
• Consistent particle-size distribution
• Comparable coating-process performance
• Regulatory documentation for the target market
• Successful pharmaceutical development and validation

Generic chemical manufacturers may be capable of producing related methacrylate copolymers, but commercial pharmaceutical substitution requires a qualified supply chain and customer-specific technical validation. This limits rapid switching and supports premium pricing for established grades.

How does amino methacrylate copolymer compare with other methacrylate excipients?

Excipient family	Typical pH behavior	Main use	Competitive position
Amino methacrylate copolymer, EUDRAGIT E	Soluble in acidic conditions	Taste masking and immediate-release protection	Specialized, relatively concentrated market
EUDRAGIT L and S	Soluble at higher intestinal pH	Enteric and delayed release	Larger and broader application base
EUDRAGIT RL and RS	Permeable, pH-independent release control	Sustained-release coatings	Used in controlled-release systems
Cellulose derivatives	Varies by grade	Film coating, viscosity control, release modification	Broad supplier base
Polyvinyl alcohol systems	Generally film-forming and water-processable	Immediate-release film coatings	Stronger competition in standard coatings
Lipid and polymer taste-masking systems	Product-specific	Sensory control	Compete at the finished-formulation level

Amino methacrylate copolymer competes primarily on functionality rather than price. For a simple film-coating application, lower-cost polymers may be viable. For bitter APIs, complex granules, or moisture-sensitive products, switching costs are higher.

What is the market size for amino methacrylate copolymer?

A reliable standalone market-size figure is not publicly disclosed. Major excipient suppliers generally report revenue by corporate segment rather than by individual polymer grade. Third-party market reports often combine acrylic polymers, enteric polymers, coating materials, and pharmaceutical excipients, making product-specific estimates difficult to verify.

The addressable market is best characterized as a small specialty segment within the global pharmaceutical excipient industry. Demand is linked to:

1. Oral solid dosage manufacturing
2. Taste-masked pediatric and geriatric products
3. Generic reformulation
4. Functional coating systems
5. Contract development and manufacturing
6. Growth in emerging-market pharmaceutical production

The market is not driven by large-volume use per finished product. Coating polymers are consumed in relatively low quantities compared with fillers, binders, and disintegrants. Revenue depends on the number of products using the material, formulation complexity, qualification status, and the supplier’s technical-service model.

What is driving demand for amino methacrylate copolymer?

Pediatric and geriatric formulations

Taste masking is a major demand driver. Pediatric medicines, orally disintegrating tablets, chewable tablets, multiparticulates, and granules require control of bitter or metallic API taste. Amino methacrylate copolymer can reduce drug release in the oral cavity while permitting release in the stomach.

Regulatory agencies continue to encourage age-appropriate dosage forms, particularly where liquid formulations create stability, dosing, or adherence problems. This supports demand for coated multiparticulates and taste-masked solid dosage forms.[3]

Generic-product differentiation

Generic manufacturers increasingly use formulation changes to compete on swallowability, dosing convenience, stability, and patient acceptability. A taste-masked or moisture-protected product can create commercial differentiation without changing the API.

The polymer is particularly relevant where a generic developer must replicate a reference product’s sensory or release characteristics while avoiding the originator’s formulation patents.

Oral solid dosage resilience

Tablets, capsules, granules, and multiparticulates remain central to pharmaceutical manufacturing. Even when injectable and biologic products grow faster in value terms, oral solid dosage products continue to represent a large manufacturing base. Amino methacrylate copolymer benefits from this installed base and from the continued development of small-molecule products.

Process and stability requirements

Moisture-sensitive APIs, hygroscopic formulations, and products requiring separation of incompatible ingredients can justify the use of a functional polymer coating. Demand rises when the polymer reduces development risk or avoids more complex packaging and processing solutions.

What factors constrain market growth?

The market has several structural limits.

First, dosage is usually low relative to bulk excipients. Volume growth therefore does not necessarily translate into proportional revenue growth.

Second, many formulations do not require a cationic methacrylate polymer. Standard tablets and capsules can use lower-cost film-coating systems, direct compression, or alternative taste-masking technologies.

Third, formulators may choose lipid coatings, ion-exchange resins, cyclodextrins, polymer blends, or encapsulation technologies depending on the API and dosage form.

Fourth, regulatory and technical qualification can delay adoption. A polymer selected during development may be difficult to replace after scale-up because changes can affect dissolution, stability, bioequivalence, and sensory performance.

Finally, demand is exposed to pharmaceutical manufacturing cycles. A product discontinuation, failed development program, or supplier change can remove material demand even when overall excipient consumption is rising.

What is the FDA regulatory status of amino methacrylate copolymer?

Amino methacrylate copolymer is used as an inactive ingredient in FDA-regulated drug products. The FDA Inactive Ingredient Database provides historical information on inactive ingredients used in approved drug products, including route, dosage form, and maximum potency data where available.[4]

The regulatory position is product-specific. Inclusion in the FDA database does not constitute a universal approval for every route, dosage form, concentration, or manufacturing process. Drug sponsors remain responsible for demonstrating that the excipient is suitable for the proposed use.

Relevant regulatory considerations include:

• Identity and composition of the polymer
• Residual solvents and residual monomers
• Elemental impurities
• Microbiological quality
• Batch-to-batch molecular and physical consistency
• Compatibility with the API
• Dissolution and release performance
• Stability under proposed storage conditions
• Suitability of the proposed concentration and route

In Europe, excipient use is assessed within the marketing authorization framework and supported by quality documentation, pharmacopoeial compliance where applicable, and product-specific safety justification. The European Pharmacopoeia and national regulatory requirements can affect specification strategy and documentation.[5]

What patents protect amino methacrylate copolymer?

The polymer chemistry itself is mature and broadly described in older patent and scientific literature. The strongest current intellectual-property positions are more likely to involve:

• Specific coating compositions
• Polymer combinations
• Taste-masking processes
• API-polymer complexes
• Multiparticulate dosage forms
• Manufacturing conditions
• Particular drug products
• Release profiles and dosing regimens

Amino methacrylate copolymer is generally an excipient platform rather than a standalone patented drug product. Product-level freedom-to-operate analysis must distinguish between patents covering the polymer, patents covering a formulation that uses the polymer, and patents covering the API or method of treatment.

Are formulation patents a commercial barrier?

Yes. A formulation patent may claim a coated particle, a specific polymer-to-API ratio, a coating thickness, a multiparticulate system, or a defined dissolution profile. Such claims can restrict a generic or follow-on developer even when the underlying polymer is commercially available.

The practical risk is highest when:

• The reference product uses a distinctive taste-masking architecture
• The formulation has a narrow dissolution specification
• The originator owns patents covering coating composition or process
• The product is pediatric or orally disintegrating
• The polymer is combined with another functional excipient in a claimed ratio

An amino methacrylate copolymer supplier normally does not control the customer’s product-specific patent position. The generic manufacturer must conduct separate freedom-to-operate and Paragraph IV analysis for the finished drug.

When does amino methacrylate copolymer lose exclusivity?

The polymer does not have a single drug-style exclusivity date. Chemical and formulation patents covering the material or its use may have expired in multiple jurisdictions, while newer patents may remain active for specific products or processes.

Commercial exclusivity is instead maintained through:

• Proprietary grades and specifications
• Manufacturing know-how
• Regulatory files and customer qualification
• Consistent global supply
• Technical support
• Long development cycles
• Switching costs after product approval

This type of protection is weaker than active pharmaceutical ingredient exclusivity but can still produce durable customer retention. A customer may avoid changing suppliers because a change could trigger comparability studies, stability work, process revalidation, or regulatory supplements.

What is the financial trajectory for amino methacrylate copolymer?

Public financial data support a positive but moderate growth profile rather than a high-growth pharmaceutical product trajectory.

Evonik does not separately report revenue or operating profit for EUDRAGIT E 100, EUDRAGIT E PO, or amino methacrylate copolymer. The products are included within the company’s Health Care and broader Nutrition & Care reporting structure. Company-level results therefore cannot be used to calculate product-specific revenue, margin, or market share.[6]

Financial trajectory indicators

Indicator	Directional effect
Growth in pediatric and geriatric dosage forms	Positive
Continued generic oral-solid-dose manufacturing	Positive
Greater demand for taste masking	Positive
Qualification of alternative suppliers	Negative for incumbent pricing
Raw-material and energy inflation	Margin pressure
Pharmaceutical customer concentration	Earnings volatility risk
Low use level per finished product	Limits volume leverage
Technical switching costs	Supports retention and pricing
Expansion in emerging markets	Positive medium-term demand
Competition from alternative polymers	Caps long-term pricing power

Revenue growth is likely to track formulation development and pharmaceutical production more closely than prescription-drug sales. A single approved product can generate recurring demand for years, but individual customer volumes may remain modest. The business has characteristics of a specialty materials franchise: recurring demand, high qualification barriers, and technical differentiation, combined with limited visibility into product-level financial performance.

How do manufacturing and supply-chain risks affect the market?

Amino methacrylate copolymer depends on acrylic monomers, polymerization capacity, solvent handling, drying, milling, quality testing, and pharmaceutical-grade documentation. Supply interruptions can affect customers even when the underlying chemistry is not scarce.

Key manufacturing barriers include:

• Control of molecular-weight distribution
• Consistent polymer composition
• Residual monomer control
• Particle-size control for powder grades
• Film-coating performance at scale
• GMP-aligned quality systems
• Change-control management
• Regulatory documentation across jurisdictions

The supplier’s manufacturing footprint and change-control discipline can matter as much as nominal price. Pharmaceutical customers generally prefer suppliers that can support global filings and provide long-term technical documentation.

What geographic markets have the strongest demand?

North America and Europe remain important because of established pharmaceutical manufacturing, mature regulatory systems, and extensive use of functional excipients. Asia-Pacific is the main volume-growth region because of expanding generic production, contract manufacturing, and pharmaceutical exports.

Region	Market characteristics
North America	High regulatory scrutiny, strong generic and specialty-product base
Europe	Mature formulation science, extensive use of functional coating polymers
India	Large generic-manufacturing base and export-oriented formulation activity
China	Expanding domestic pharmaceutical production and excipient capability
Japan and South Korea	High-quality manufacturing and advanced dosage-form development
Latin America	Growth tied to local manufacturing and imported formulation technology
Middle East and Africa	Smaller base, with demand linked to imported and locally packaged medicines

Growth in Asia-Pacific does not automatically translate into equivalent supplier revenue. Local manufacturers may seek lower-cost alternatives, regional sourcing, or localized production. Premium branded polymers retain an advantage where regulatory risk and product consistency outweigh material-cost savings.

Which companies are challenging the market leader?

No fully transparent public ranking identifies all suppliers of chemically equivalent amino methacrylate copolymers. Competition comes from three groups:

1. Established pharmaceutical-polymer suppliers offering alternative methacrylate grades
2. Regional excipient manufacturers producing comparable acrylic polymers
3. Formulation-technology companies offering non-polymer taste-masking or coating systems

The most meaningful competitive threat is often substitution at the formulation level rather than direct chemical replication. A customer may replace amino methacrylate copolymer with an ion-exchange resin, lipid system, cellulose derivative, or polymer blend if the alternative meets dissolution, sensory, stability, and regulatory requirements.

What is the generic launch risk associated with this excipient?

The excipient itself creates limited generic launch risk. The greater risk comes from the finished drug product.

A generic launch may face:

• Orange Book-listed patents on the reference drug
• Paragraph IV litigation
• Formulation patents
• Method-of-use patents
• Bioequivalence challenges
• Dissolution-profile differences
• Taste-masking performance requirements
• Regulatory scrutiny over excipient concentration or composition

Amino methacrylate copolymer can help a generic developer match a reference product’s performance, but its use does not eliminate patent risk. FDA Orange Book listings must be reviewed for the specific drug product, and patent certifications must be assessed under the ANDA pathway.[7]

How strong is the commercial position of amino methacrylate copolymer?

The commercial position is strongest where the polymer is embedded in a validated, approved dosage form and performs a function that is difficult to reproduce. It is weaker in standard coatings where price and supplier competition are more important.

The market can be summarized as follows:

Factor	Assessment
Demand growth	Moderate
Product differentiation	High at formulation level
Direct supplier concentration	High based on visible branded supply
Patent protection	Product- and formulation-specific
Regulatory barrier	Moderate to high
Switching cost	Moderate to high after approval
Volume intensity	Low to moderate
Pricing power	Moderate for qualified grades
Biosimilar relevance	Low
Generic-drug relevance	High
Financial transparency	Low

Biosimilar risk is limited because amino methacrylate copolymer is used mainly in oral small-molecule dosage forms. Biologic and biosimilar manufacturing relies on a different excipient set, including buffers, stabilizers, surfactants, and tonicity agents. The principal competitive exposure is therefore generic substitution and alternative oral formulation technology, not biosimilar erosion.

What is the outlook for amino methacrylate copolymer?

The medium-term outlook is stable to moderately positive. Growth should come from:

• Pediatric taste-masked products
• Orally disintegrating and chewable dosage forms
• Generic product differentiation
• Moisture-sensitive APIs
• Multiparticulate delivery systems
• Pharmaceutical manufacturing expansion in Asia

The main constraints are limited dose consumption, competition from alternative excipients, lack of product-level market transparency, and exposure to customer-specific development cycles.

The most defensible investment or commercial view is that amino methacrylate copolymer is a niche, technically differentiated pharmaceutical-materials business with recurring demand and meaningful qualification barriers. It is unlikely to produce drug-like revenue growth, but it can support attractive specialty-excipient economics when linked to approved products and long-term customer validation.

Key Takeaways

• Amino methacrylate copolymer is used mainly for taste masking, immediate-release coating, moisture protection, and multiparticulate formulations.
• Evonik’s EUDRAGIT E 100 and EUDRAGIT E PO are the principal publicly visible commercial products.
• No reliable public source discloses a standalone global market size or product-level revenue.
• Demand is tied to oral solid dosage forms, pediatric medicines, geriatric products, and differentiated generics.
• The excipient has no single drug-style loss-of-exclusivity date.
• Commercial defensibility comes from formulation know-how, regulatory qualification, supply reliability, and switching costs.
• Formulation and finished-drug patents create more important legal risks than patents covering the polymer itself.
• Biosimilar exposure is low; generic-drug exposure is high.
• Financial growth is likely to be moderate, with stronger pricing and retention in technically complex formulations.

FAQs

Is amino methacrylate copolymer the same as EUDRAGIT E 100?

EUDRAGIT E 100 is a branded pharmaceutical grade of amino methacrylate copolymer. Product identity, specifications, and regulatory documentation must be confirmed for the specific grade.

Is amino methacrylate copolymer safe for oral medicines?

It is used in approved oral pharmaceutical products, subject to product-specific concentration, route, quality, and regulatory review. Safety cannot be assessed solely from the polymer name.

Can amino methacrylate copolymer be replaced by a cellulose polymer?

Sometimes. Replacement depends on taste-masking efficiency, pH-solubility behavior, film strength, API compatibility, dissolution, stability, and regulatory comparability.

Does amino methacrylate copolymer require an ANDA Paragraph IV certification?

No. Paragraph IV certifications apply to patents listed for a specific reference drug in the FDA Orange Book. Use of the excipient alone does not trigger a Paragraph IV filing.

Does Evonik disclose EUDRAGIT E revenue separately?

No. Public financial reporting does not separately disclose revenue or profit for individual EUDRAGIT grades, including amino methacrylate copolymer products.

References

1. Evonik Industries AG. (n.d.). EUDRAGIT E 100 and EUDRAGIT E PO: Product information and pharmaceutical applications. Evonik Health Care.

2. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press.

3. U.S. Food and Drug Administration. (2016). E11(R1) addendum: Clinical investigation of medicinal products in the pediatric population. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

6. Evonik Industries AG. (2024). Annual report 2023. Evonik Industries AG.

7. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.